scispace - formally typeset
F

Fabrice Barlesi

Researcher at Aix-Marseille University

Publications -  666
Citations -  36214

Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.

Papers
More filters
Journal ArticleDOI

Traitements de deuxième ligne du cancer bronchique non à petites cellules métastatique : quels choix aujourd’hui ? Quelles perspectives demain ?

Laurent Greillier, +1 more
- 01 Jan 2012 - 
Journal ArticleDOI

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Clemence Demerle, +14 more
- 04 Nov 2022 - 
TL;DR: In this paper , the anti-HVEM18-10 mAb increases primary human αβ-T cells activity alone or in the presence of HVEM-expressing lung or colorectal cancer cells in vitro (TRANS-activity).

MAINTENANCE BEVACIZUMAB (BV) WITH OR WITHOUT PEMETREXED (PEM) FOLLOWING FIRST-LINE BV-CISPLATIN (CIS)-PEM IN PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY SAFETY DATA FROM AVAPERL1 (MO22089) in ANNALS OF ONCOLOGY, vol 21, issue , pp 144-144

Fabrice Barlesi, +8 more
Journal ArticleDOI

270 Étude par potentiels évoqués cognitifs de la neurotoxicité subaiguë des chimiothérapies avec sels de platine

J. Vion-Dury, +7 more
- 01 Jan 2007 - 
Journal ArticleDOI

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Jaafar Bennouna, +12 more
TL;DR: Although the stringent primary endpoint was not met, this stop-and-go strategy with platinum-based chemotherapy plus bevacizumab continuation beyond progression compares favourably with standard schedule, deserving to be further studied in advanced non-squamous NSCLC.